Strong Revenue ReboundA >4x revenue jump in 2025 shows meaningful top-line traction and market demand; sustained revenue growth over the next 2–6 months would provide runway to scale gross margins, justify continued investment, and reduce dependence on financing if cost structure stabilizes.

Substantial Equity BufferA large equity base (~2.0bn) offers a capital cushion against short-term shocks and supports funding flexibility. Over several months this buffer can absorb operating losses, limit immediate insolvency risk, and provide capacity for strategic financing or asset investment.

Asset Expansion Supports Growth CapacityMarked asset expansion implies investment in capacity, R&D, or commercial infrastructure. If deployed effectively, these assets support sustained revenue growth and operational scale over months, enabling the company to capture market share as demand grows.

Bears Say

Persistent Negative ProfitabilityLarge gross and net losses across recent years suggest the core business model or cost base remains unprofitable. Without durable gross-margin improvement, continued losses will erode equity over months and undermine long-term viability even if revenue rises.

Ongoing Operating Cash BurnConsistent negative operating cash flow indicates the business is not self-funding and requires external financing. Continued cash burn over 2–6 months increases refinancing and dilution risk, constraining the company's ability to invest or withstand market setbacks.

Elevated Leverage And Refinancing RiskMaterial rise in debt levels raises interest and covenant pressure; with ongoing losses and negative cash flow, elevated leverage increases the likelihood of difficult refinancing or equity dilution within months, limiting strategic flexibility and raising creditor risk.

1DO FAQ

What was Doxa AB’s price range in the past 12 months?

Doxa AB lowest stock price was €0.00 and its highest was €0.07 in the past 12 months.

What is Doxa AB’s market cap?

Doxa AB’s market cap is €53.05M.

When is Doxa AB’s upcoming earnings report date?

Doxa AB’s upcoming earnings report date is Apr 21, 2026 which is in 42 days.

How were Doxa AB’s earnings last quarter?

Doxa AB released its earnings results on Feb 27, 2026. The company reported -€0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.007.

Is Doxa AB overvalued?

According to Wall Street analysts Doxa AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Doxa AB pay dividends?

Doxa AB does not currently pay dividends.

What is Doxa AB’s EPS estimate?

Doxa AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Doxa AB have?

Doxa AB has 1,285,530,600 shares outstanding.

What happened to Doxa AB’s price movement after its last earnings report?

Doxa AB reported an EPS of -€0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Doxa AB?

Currently, no hedge funds are holding shares in DE:1DO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Doxa AB

Doxa AB (publ), a dental company, develops, manufactures, and commercializes bioceramic dental products under the Ceramir brand worldwide. It offers Crown & Bridge, a dental cement that is used for permanent cementing of crowns and bridges. The company was founded in 1987 and is based in Uppsala, Sweden.